Bio-Rad Laboratories, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Norman D. Schwartz
- Full Time Employees
- 7,450
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 1000 Alfred Nobel Drive Hercules CA United States 94547
- IPO Date
- Mar 17, 1980
- CIK
- 0000012208
- Website
- bio-rad.com
- Similar Companies
- Business
- Bio-Rad Laboratories, Inc. is a global leader in the development and manufacture of life science research and clinical diagnostics products. Founded in 1952 and headquartered in Hercules, California, the company operates internationally across the United States, Europe, Asia, Canada, and Latin America. Bio-Rad's core products span life science research instruments and consumables, including chromatography resins and media, flow cytometry antibodies, Droplet Digital PCR (ddPCR) platforms and reagents, as well as advanced digital PCR solutions designed for genomic research and applied sciences. In clinical diagnostics, Bio-Rad offers systems and assays for autoimmune testing, infectious disease detection, diabetes monitoring, blood typing and screening, cardiac assessment controls, molecular quality controls, veterinary diagnostics, and water quality testing. The company serves a broad range of customers from research institutions to clinical, hospital, and veterinary laboratories. Recent major changes include the acquisition of Stilla Technologies in the second quarter of 2025, which enhances Bio-Rad's digital PCR portfolio by integrating Stilla’s QX700 series instruments with Bio-Rad's existing QX Continuum system, thereby accelerating innovation in molecular diagnostics and precision medicine. In 2024, Bio-Rad also completed the acquisition of Saber Bio, a company focused on droplet technology for antibody discovery, aligning with its expansion in cell biology products. Additionally, Bio-Rad has launched new products such as the StarBright dyes for flow cytometry to improve multiplexing capabilities and kits for precise mutation detection in oncology applications leveraging its ddPCR technology. These developments support the company’s strategic focus on enhancing automation, throughput, and the sensitivity of its diagnostics platforms, further positioning it as a key player in advancing life science research and clinical diagnostic solutions. Bio-Rad continues to invest in transformative technologies such as Droplet Digital PCR for non-invasive cancer screening and gene therapy production, supported by ongoing product development and expansion of its assay portfolio. The company’s broad product offering includes instruments, software, reagents, and specialized consumables designed to support applications in cell biology, gene expression, protein purification, drug discovery, infectious diseases, and transfusion medicine. With a commitment to innovation and global healthcare advancement, Bio-Rad maintains a strong presence in both the life sciences and clinical diagnostics markets, driving growth through strategic acquisitions, product launches, and enhanced service offerings.
Company News
Medicus Pharma to Present at BIO-Europe 2026
What Bio-Rad Laboratories (BIO) Said on Its Q3 Earnings Call
Bio-Rad Laboratories, Inc. (BIO) Q3 2026 Earnings Call Transcript
Bio-Rad Laboratories (BIO) Q3 Earnings Top Estimates
Bio-Rad Reports Third-Quarter 2026 Financial Results
BIO-TECHNE DECLARES DIVIDEND
Cipher, a Prosegur Company, and BIO-key Announce Technology Integration to Expand Identity Security Offering, Starting in Portugal
Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare Conference
BIO-key Deploys Identity Security Solution to New Customer Within a Middle East Government's National Security Ecosystem
Ariel Appreciation Fund Q3 2026 Scorecard: Buys, Sells, And Standouts
Ariel Fund Q3 2026 Leaders And Laggards
BIO-key Secures Another Middle East Government Contract for its Passwordless, Biometric, Identity and Access Management Solutions
Bio-Rad Laboratories Inc (BIO) Stock Down 3.0% but Still Overvalued -- GF Score: 73/100
Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
BIO-key Names Cybersecurity Veteran Stephen Morrow President of PortalGuard to Drive Accelerated Adoption of its Innovative IAM Solution
BIO-key Adds New Middle East Government Security Agency Customer, Expanding Regional Footprint
Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform
PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026
BIO-key Partners with Al Majlis Group to Expand Identity Security Across Arabian Gulf
Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth